^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

CD123 positive

i
Other names: IL3RA, Interleukin 3 receptor subunit alpha, CD123, Interleukin 3 Receptor Alpha, IL-3 Receptor Subunit Alpha, IL-3R Subunit Alpha, CD123 Antigen, IL-3R-Alpha, IL-3RA , IL3R, IL-3 Receptor Alpha SP2 Isoform
Entrez ID:
Related biomarkers:
Phase 1/2
ImmunoGen, Inc.
Active, not recruiting
Last update posted :
04/18/2024
Initiation :
11/06/2019
Primary completion :
12/11/2024
Completion :
12/11/2024
IL3RA
|
CD123 positive • IL3RA positive
|
Venclexta (venetoclax) • azacitidine • decitabine • pivekimab sunirine (IMGN632)
Phase 2
Joshua Zeidner
Not yet recruiting
Last update posted :
04/04/2024
Initiation :
04/01/2024
Primary completion :
08/01/2027
Completion :
12/01/2027
IL3RA
|
CD123 positive
|
azacitidine • Elzonris (tagraxofusp-erzs)
Phase 1
Affimed GmbH
Recruiting
Last update posted :
03/13/2024
Initiation :
03/21/2023
Primary completion :
03/01/2025
Completion :
03/01/2026
IL3RA
|
CD123 positive • IL3RA positive
|
AFM28
Phase 1
Jonsson Comprehensive Cancer Center
Withdrawn
Last update posted :
03/08/2024
Initiation :
08/03/2024
Primary completion :
08/03/2025
Completion :
08/03/2026
CD123 • IL3RA
|
CD123 positive • CD123 expression • IL3RA expression
|
azacitidine • Elzonris (tagraxofusp-erzs)
Phase 1
City of Hope Medical Center
Active, not recruiting
Last update posted :
01/30/2024
Initiation :
12/15/2015
Primary completion :
12/15/2024
Completion :
12/15/2024
FLT3 • CD123 • IL3RA
|
CD123 positive
|
cyclophosphamide • fludarabine IV • CD123R(EQ)28zeta/EGFRt+ T cells • MB-102
Phase 2
M.D. Anderson Cancer Center
Recruiting
Last update posted :
12/11/2023
Initiation :
05/06/2022
Primary completion :
12/31/2026
Completion :
12/31/2026
IL3RA
|
CD123 positive • CD123 expression • IL3RA expression
|
vibecotamab (XmAb14045)
Phase 1/2
M.D. Anderson Cancer Center
Recruiting
Last update posted :
10/16/2023
Initiation :
02/17/2022
Primary completion :
07/01/2025
Completion :
07/01/2025
IL3RA
|
CD123 positive
|
Rituxan (rituximab) • cytarabine • cyclophosphamide • methotrexate • vincristine • leucovorin calcium • Elzonris (tagraxofusp-erzs) • mercaptopurine • Hemady (dexamethasone tablets) • Neulasta (pegfilgrastim) • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate)
Phase 1/2
Children's Oncology Group
Withdrawn
Last update posted :
09/01/2023
Initiation :
08/01/2023
Primary completion :
09/01/2023
Completion :
09/01/2023
IL3RA
|
CD123 positive • IL3RA positive
|
methotrexate • Vyxeos (cytarabine/daunorubicin liposomal formulation) • fludarabine IV • pivekimab sunirine (IMGN632) • Starasid (cytarabine ocfosfate)
Phase 1/2
Chongqing Precision Biotech Co., Ltd
Recruiting
Last update posted :
08/30/2023
Initiation :
08/31/2023
Primary completion :
12/31/2025
Completion :
08/31/2026
IL6 • CD123 • IL3RA
|
CD123 positive • CD123 expression • IL3RA positive
|
cyclophosphamide • CD123 targeted CAR-NK
Phase 1
AvenCell Europe GmbH
Recruiting
Last update posted :
08/17/2023
Initiation :
01/28/2020
Primary completion :
05/01/2025
Completion :
09/01/2025
IL3RA
|
CD123 positive
|
cyclophosphamide • fludarabine IV • AVC-101
Phase 1/2
ImmunoGen, Inc.
Active, not recruiting
Last update posted :
08/03/2023
Initiation :
01/02/2018
Primary completion :
12/01/2024
Completion :
12/01/2025
IL3RA
|
CD123 positive • CD123 expression • IL3RA expression
|
pivekimab sunirine (IMGN632)
Phase 1
Affiliated Hospital to Academy of Military Medi...
Recruiting
Last update posted :
04/26/2023
Initiation :
10/01/2022
Primary completion :
10/30/2023
Completion :
10/30/2024
CD123 • IL3RA
|
CD123 positive
|
JD023
Phase 1/2
Chongqing Precision Biotech Co., Ltd
Recruiting
Last update posted :
04/18/2023
Initiation :
12/01/2019
Primary completion :
12/31/2023
Completion :
07/01/2024
CD123 • IL3RA
|
CD123 positive • CD123 expression • IL3RA expression • IL3RA positive
|
CD123 CAR-T cell therapy
Phase 1/2
Chongqing Precision Biotech Co., Ltd
Recruiting
Last update posted :
04/18/2023
Initiation :
09/01/2019
Primary completion :
12/31/2023
Completion :
07/01/2024
CD123 • IL3RA
|
CD123 positive • CD123 expression • IL3RA expression • IL3RA positive
|
CD123 CAR-T cell therapy
Phase N/A
MacroGenics
No Longer Available
Last update posted :
05/30/2022
IL3RA
|
CD123 positive • IL3RA positive
|
flotetuzumab (MGD006)
Phase 1b
Aptevo Research and Development LLC
Recruiting
Last update posted :
02/10/2022
Initiation :
12/13/2018
Primary completion :
12/15/2022
Completion :
06/15/2023
FLT3 • RUNX1 • ASXL1 • IL3RA
|
ASXL1 mutation • CD123 positive • IL3RA positive
|
APVO436
Phase 1b
Aptevo Therapeutics
Withdrawn
Last update posted :
12/01/2021
Initiation :
01/01/2025
Primary completion :
01/01/2026
Completion :
01/01/2027
IL3RA
|
CD123 positive • IL3RA positive
|
Venclexta (venetoclax) • azacitidine • APVO436
Phase N/A
Hebei Senlang Biotechnology Inc., Ltd.
Recruiting
Last update posted :
03/12/2021
Initiation :
12/16/2020
Primary completion :
12/16/2021
Completion :
02/16/2022
IFNG • IL6 • TNFA • IL10 • IL3RA
|
CD123 positive • IL3RA positive
|
cyclophosphamide
Phase N/A
UNC Lineberger Comprehensive Cancer Center
Completed
Last update posted :
01/13/2021
Initiation :
03/01/2018
Primary completion :
10/28/2020
Completion :
10/28/2020
KIT • CD33 • CD34 • IL3RA
|
CD123 positive • IL3RA positive
Phase 1
Cellectis S.A.
Withdrawn
Last update posted :
07/14/2020
Initiation :
07/11/2019
Primary completion :
12/05/2019
Completion :
12/05/2019
IL3RA
|
CD123 positive • IL3RA positive
|
UCART123
Phase 1
Hebei Senlang Biotechnology Inc., Ltd.
Unknown status
Last update posted :
01/11/2019
Initiation :
12/26/2018
Primary completion :
11/06/2020
Completion :
06/06/2021
IL3RA
|
CD123 positive • IL3RA positive
|
SENL401